This advisory introduces readers to digital therapeutics (DTx) and the benefits of their use in behavioral health. It describes the research, regulatory, and reimbursement implications for DTx as well as selection and implementation considerations.

This advisory reviews diabetes and how it relates to mental illness, stress, and substance use disorders. It highlights ways to integrate diabetes care into behavioral health treatment, such as screening and intake, staff education, integrated care, and counseling support.

This advisory gives an overview of extended-release injectable naltrexone for people with opioid dependence. It discusses how it differs from other medication-assisted treatments, safety concerns, and patients most likely to benefit.

This advisory defines protracted withdrawal and identifies specific withdrawal symptoms associated with alcohol, opioids, methamphetamine, cocaine, marijuana, and benzodiazepines. The advisory also explains how protracted withdrawal differs from acute withdrawal, and gives tips to help clients manage it in recovery.